Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis

Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis

Laura Kreckler,1 Mark Osinski,1 Scott Williams,1 Roger Whiting2 1Covance Laboratories Inc., Madison, WI, 53704-2523, USA; 2Altos Therapeutics LLC, Los Altos, CA, 94022, USACorrespondence: Laura Kreckler, AbbVie, 1 North Waukegan Road, North Chicago, IL, 60064, USA, Tel +1 847 937 5744, Fax +1 847 93...

Full description

Bibliographic Details
Main Authors: Kreckler L, Osinski M, Williams S, Whiting R
Format: Article
Language:English
Published: Dove Medical Press 2022-02-01
Series:Journal of Experimental Pharmacology
Subjects:
dopamine d2/d3 selective receptor antagonist
gastroparesis
methods
safety pharmacology
Online Access:https://www.dovepress.com/non-clinical-safety-pharmacology-evaluations-of-trazpiroben-tak-906-a--peer-reviewed-fulltext-article-JEP

Internet

https://www.dovepress.com/non-clinical-safety-pharmacology-evaluations-of-trazpiroben-tak-906-a--peer-reviewed-fulltext-article-JEP

Similar Items